An Open-label Extension Study of Subcutaneously Administered ALN-AT3SC in Patients with Moderate or Severe Hemophilia A or B who have Participated in a Previous Clinical Study with ALN-AT3SC

Trial Profile

An Open-label Extension Study of Subcutaneously Administered ALN-AT3SC in Patients with Moderate or Severe Hemophilia A or B who have Participated in a Previous Clinical Study with ALN-AT3SC

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Fitusiran (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 10 Jul 2017 Results published in an Alnylam Pharmaceuticals Media Release
    • 10 Jul 2017 Results published in a Sanofi Genzyme media release.
    • 10 Jul 2017 According to a Sanofi Genzyme media release, results were presented in an oral presentation at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top